

Gregor Berger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8153051/publications.pdf>

Version: 2024-02-01

97
papers

5,449
citations

76326

40
h-index

85541

71
g-index

102
all docs

102
docs citations

102
times ranked

5267
citing authors

#	ARTICLE	IF	CITATIONS
1	Maladaptive Avoidance Learning in the Orbitofrontal Cortex in Adolescents With Major Depression. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2022, 7, 293-301.	1.5	2
2	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. <i>Brain, Behavior, and Immunity</i> , 2022, 99, 147-156.	4.1	2
3	Home treatment as an addition to family-based treatment in adolescents with anorexia nervosa: A pilot study. <i>European Eating Disorders Review</i> , 2022, 30, 168-177.	4.1	7
4	The mental distress of our youth in the context of the COVID-19 pandemic. <i>Swiss Medical Weekly</i> , 2022, 152, w30142.	1.6	15
5	Deficient prefrontal-amygdalar connectivity underlies inefficient face processing in adolescent major depressive disorder. <i>Translational Psychiatry</i> , 2022, 12, 195.	4.8	7
6	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 874-881.	1.7	10
7	Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. <i>Microbial Biotechnology</i> , 2021, 15, 642-651.	1.7	11
8	Feasibility and acceptability of home treatment as an addition to family based therapy for adolescents with anorexia nervosa. A case series. <i>International Journal of Eating Disorders</i> , 2021, 54, 1707-1710.	4.0	10
9	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.1	5
10	How Are Discrepant Parent-Child Reports Integrated? A Case of Depressed Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 279-287.	1.3	3
11	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020, 87, 243-252.	1.3	48
12	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020, 226, 52-60.	2.0	8
13	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. <i>Schizophrenia Research</i> , 2020, 226, 44-51.	2.0	27
14	Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes. <i>Schizophrenia Research</i> , 2020, 216, 255-261.	2.0	8
15	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.1	16
16	M22. IGG ANTIBODIES TO TOXOPLASMA GONDII ARE ASSOCIATED WITH INCREASED LONG-TERM RISK FOR PSYCHOSIS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S141-S142.	4.3	2
17	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. <i>Schizophrenia Research</i> , 2020, 223, 271-278.	2.0	9
18	Verbal Memory Performance in Depressed Children and Adolescents: Associations with EPA but Not DHA and Depression Severity. <i>Nutrients</i> , 2020, 12, 3630.	4.1	7

#	ARTICLE	IF	CITATIONS
19	The stressâ€“Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches. <i>Translational Psychiatry</i> , 2020, 10, 315.	4.8	20
20	Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?. <i>Schizophrenia Research</i> , 2020, 220, 275-277.	2.0	3
21	ADHD: Current Concepts and Treatments in Children and Adolescents. <i>Neuropediatrics</i> , 2020, 51, 315-335.	0.6	117
22	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 48-54.	2.0	8
23	Omega-3 and its domain-specific effects on cognitive test performance in youths: A meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 420-436.	6.1	22
24	When parents and children disagree: Informant discrepancies in reports of depressive symptoms in clinical interviews. <i>Journal of Affective Disorders</i> , 2020, 272, 223-230.	4.1	13
25	Validation of a Food Frequency Questionnaire to Assess Intake of n-3 Polyunsaturated Fatty Acids in Switzerland. <i>Nutrients</i> , 2019, 11, 1863.	4.1	18
26	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 393.	2.6	22
27	Anxious depression as a clinically relevant subtype of pediatric major depressive disorder. <i>Journal of Neural Transmission</i> , 2019, 126, 1217-1230.	2.8	7
28	Omega-3 Fatty Acids as a Treatment for Pediatric Depression. A Phase III, 36 Weeks, Multi-Center, Double-Blind, Placebo-Controlled Randomized Superiority Study. <i>Frontiers in Psychiatry</i> , 2019, 10, 863.	2.6	8
29	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019, 206, 67-74.	2.0	46
30	The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B12, B6, and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis. <i>Biological Psychiatry</i> , 2019, 86, 35-44.	1.3	23
31	Clinical trajectories in the ultra-high risk for psychosis population. <i>Schizophrenia Research</i> , 2018, 197, 550-556.	2.0	54
32	Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes â€“ A Tool to Study Neurodevelopmental Disorders as ADHD. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 321.	3.7	22
33	Dynamic prediction of transition to psychosis using joint modelling. <i>Schizophrenia Research</i> , 2018, 202, 333-340.	2.0	18
34	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	7.4	141
35	NEURAPROâ€™ study protocol: a multicentre randomized controlled trial of omegaâ€“3 fatty acids and cognitiveâ€“behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. <i>Microbial Biotechnology</i> , 2017, 11, 418-428.	1.7	55
36	Effect of Î‰-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 19.	11.0	216

#	ARTICLE	IF	CITATIONS
37	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 292-299.	8.8	20
38	Ventricular volumes across stages of schizophrenia and other psychoses. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1041-1051.	2.3	17
39	Lithium suppression of tau induces brain iron accumulation and neurodegeneration. <i>Molecular Psychiatry</i> , 2017, 22, 396-406.	7.9	66
40	Comments on Bozzatello et al. Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. <i>J. Clin. Med.</i> 2016, 5, 67. <i>Journal of Clinical Medicine</i> , 2016, 5, 69.	2.4	12
41	Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis. <i>PLoS ONE</i> , 2016, 11, e0148429.	2.5	28
42	Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. <i>Molecular Psychiatry</i> , 2014, 19, 317-324.	7.9	58
43	Polyunsaturated fatty acids in emerging psychosis: a safer alternative?. <i>Microbial Biotechnology</i> , 2014, 8, 199-208.	1.7	28
44	Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. , 2013, , 149-178.		0
45	Eicosapentaenoic Acid Interventions in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 179-185.	1.4	109
46	Polyunsaturated Fatty Acids in Emerging Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 576-591.	1.9	16
47	Neuroprotective Effects of Low-dose Lithium in Individuals at Ultra-high Risk for Psychosis. A Longitudinal MRI/MRS Study. <i>Current Pharmaceutical Design</i> , 2012, 18, 570-575.	1.9	54
48	Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2012, 135, 175-180.	2.0	22
49	Pituitary volume increase during emerging psychosis. <i>Schizophrenia Research</i> , 2011, 125, 41-48.	2.0	57
50	Chronic modulation of serotonergic neurotransmission with sertraline attenuates the loudness dependence of the auditory evoked potential in healthy participants. <i>Psychopharmacology</i> , 2011, 217, 101-110.	3.1	29
51	Relational Memory in First Episode Psychosis: Implications for Progressive Hippocampal Dysfunction After Illness Onset. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 206-213.	2.3	17
52	Phospholipase A ₂ activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 598-607.	2.6	24
53	Randomized Controlled Trial of Interventions for Young People at Ultra High Risk for Psychosis. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 430-440.	2.2	128
54	Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. <i>Journal of Psychiatric Research</i> , 2010, 44, 447-453.	3.1	82

#	ARTICLE	IF	CITATIONS
55	Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: A pilot study. <i>Journal of Psychiatric Research</i> , 2010, 44, 1027-1034.	3.1	50
56	Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 180-182.	1.8	28
57	Caudate nucleus volume in individuals at ultra-high risk of psychosis: A cross-sectional magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 223-230.	1.8	41
58	The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: A longitudinal MRI study. <i>Schizophrenia Research</i> , 2010, 116, 49-54.	2.0	29
59	Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects?. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 214-5; author reply 215.	2.4	2
60	Neurobiological endophenotypes of psychosis and schizophrenia. , 2009, , 61-80.		7
61	Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation. <i>Neurobiology of Disease</i> , 2009, 33, 354-357.	4.4	107
62	The reliability and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode psychosis. <i>Addictive Behaviors</i> , 2009, 34, 821-825.	3.0	59
63	The International Study on General Practitioners and Early Psychosis (IGPS). <i>Schizophrenia Research</i> , 2009, 108, 182-190.	2.0	35
64	Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients. <i>Schizophrenia Research</i> , 2009, 113, 65-71.	2.0	32
65	Intervention in Individuals at Ultra-High Risk for Psychosis. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1206-1212.	2.2	258
66	The topical niacin sensitivity test: An inter- and intra-rater reliability study in healthy controls. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2008, 79, 15-19.	2.2	2
67	Adhesio interthalamica in individuals at high-risk for developing psychosis and patients with psychotic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1708-1714.	4.8	32
68	A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis. <i>Schizophrenia Research</i> , 2008, 102, 163-170.	2.0	52
69	Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study. <i>Neuropsychopharmacology</i> , 2008, 33, 2467-2473.	5.4	107
70	Pilot Study Evaluating the Effect of Massage Therapy on Stress, Anxiety and Aggression in a Young Adult Psychiatric Inpatient Unit. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 414-422.	2.3	29
71	Declining Transition Rate in Ultra High Risk (Prodromal) Services: Dilution or Reduction of Risk?. <i>Schizophrenia Bulletin</i> , 2007, 33, 673-681.	4.3	376
72	Aneurysms of Pericallosal Cerebral Artery Haemorrhage with Consecutive Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 554-554.	2.3	2

#	ARTICLE	IF	CITATIONS
73	Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. <i>British Journal of Psychiatry</i> , 2007, 191, s69-s75.	2.8	128
74	Olfactory sensitivity through the course of psychosis: Relationships to olfactory identification, symptomatology and the schizophrenia odour. <i>Psychiatry Research</i> , 2007, 149, 97-104.	3.3	19
75	Monitoring the Safe Use of Clozapine. <i>CNS Drugs</i> , 2007, 21, 117-127.	5.9	50
76	Omega-3 Fatty Acids Supplementation in Children with Autism: A Double-blind Randomized, Placebo-controlled Pilot Study. <i>Biological Psychiatry</i> , 2007, 61, 551-553.	1.3	307
77	Antibodies to Infectious Agents in Individuals at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2007, 61, 1215-1217.	1.3	66
78	PACE: a specialised service for young people at risk of psychotic disorders. <i>Medical Journal of Australia</i> , 2007, 187, S43-6.	1.7	78
79	Neuroprotection in emerging psychotic disorders. <i>Microbial Biotechnology</i> , 2007, 1, 114-127.	1.7	45
80	HPA axis functioning associated with transition to psychosis: Combined DEX/CRH test. <i>Journal of Psychiatric Research</i> , 2007, 41, 446-450.	3.1	47
81	Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1867-1875.	2.2	139
82	Bioactive lipids in schizophrenia. <i>International Review of Psychiatry</i> , 2006, 18, 85-98.	2.8	67
83	Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. <i>Schizophrenia Research</i> , 2006, 84, 67-76.	2.0	77
84	The role of phospholipases A2 in schizophrenia. <i>Molecular Psychiatry</i> , 2006, 11, 547-556.	7.9	65
85	Insight, symptoms and executive functions in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2006, 11, 437-451.	1.3	27
86	Stress, the Hippocampus and the Hypothalamic-Pituitary-Adrenal Axis: Implications for the Development of Psychotic Disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 725-741.	2.3	186
87	Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 725-741.	2.3	12
88	Neurobiology of early psychosis. <i>British Journal of Psychiatry</i> , 2005, 187, s8-s18.	2.8	58
89	Structural Brain Imaging Evidence for Multiple Pathological Processes at Different Stages of Brain Development in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2005, 31, 672-696.	4.3	479
90	Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. <i>Biological Psychiatry</i> , 2005, 57, 399-405.	1.3	70

#	ARTICLE	IF	CITATIONS
91	Pituitary Volume Predicts Future Transition to Psychosis in Individuals at Ultra-High Risk of Developing Psychosis. <i>Biological Psychiatry</i> , 2005, 58, 417-423.	1.3	202
92	Insight in Relation to Psychosocial Adjustment in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2004, 192, 442-445.	1.0	18
93	Potential use of the topical niacin skin test in early psychosis—a combined approach using optical reflection spectroscopy and a descriptive rating scale. <i>Journal of Psychiatric Research</i> , 2003, 37, 237-247.	3.1	49
94	Proton Magnetic Resonance Spectroscopy in First Episode Psychosis and Ultra High-Risk Individuals. <i>Schizophrenia Bulletin</i> , 2003, 29, 831-843.	4.3	113
95	Implications of lipid biology for the pathogenesis of schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2002, 36, 355-366.	2.3	61
96	Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 885-891.	2.2	56
97	Genetic vulnerability. , 0, , 31-46.		0